Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
48.07
+0.11 (0.22%)
Dec 3, 2024, 1:59 PM EST - Market open
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B EUR
Revenue Growth
+6.01%
P/S Ratio
n/a
Revenue / Employee
562,738 EUR
Employees
86,088
Market Cap
120.79B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
| Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elevance Health | 174.02B |
| Pfizer | 59.38B |
| Bristol-Myers Squibb Company | 47.44B |
| Medtronic | 33.00B |
| Amgen | 32.53B |
| Gilead Sciences | 28.30B |
| Danaher | 23.74B |
| Stryker | 21.97B |
SNY News
- 1 day ago - Sanofi to invest $1 bln in insulin production site in Beijing, local authority says - Reuters
- 6 days ago - Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics - CNBC
- 11 days ago - Sanofi plans to change hospital drug-discount program, WSJ reports - Reuters
- 18 days ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 18 days ago - Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewsWire
- 19 days ago - Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma - GlobeNewsWire
- 20 days ago - Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform - Business Wire
- 20 days ago - Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive - Seeking Alpha